Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: Meaningful at PSA < 5 ng/ml?

Molecular Imaging and Biology

Volumn 8, Issue 1, 2006, Pages 43-48

  Heinisch, Martin ^a   Dirisamer, Albert ^b   Loidl, Wolfgang ^a   Stoiber, Franz ^a   Gruy, Bernhard ^a   Haim, Silke ^a   Langsteger, Werner ^a  

^a St Vincent's Hospital Linz   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

F 18 fluorocholine; PET CT; Prostate specific antigen (PSA); Restaging of prostate cancer

Indexed keywords

BICALUTAMIDE; FLUOROCHOLINE; FLUORODEOXYGLUCOSE F 18; GOSERELIN; IASOCHOLINE; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CHOLINE; DIAGNOSTIC AGENT; FLUORINE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER HORMONE THERAPY; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION FUNCTION; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG METABOLISM; DRUG UPTAKE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MALE; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; BLOOD; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; RETROSPECTIVE STUDY; SCINTISCANNING;

AGED; AGED, 80 AND OVER; CHOLINE; FLUORINE RADIOISOTOPES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33645835922     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-005-0023-2     Document Type: Article

References (29)

1. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ (2004) Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol 172:910-914
2. Kamat AM, Rosser CJ, Levy LB, et al. (2004) Rise in serum PSA of 1.5 ng/ mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure. Urology 63:1132-1137
3. Moul JW (2000) Prostate specific antigen only progression of prostate cancer. J Urol 163:1632-1642
4. Huch Boni RA, Meyenberger C, Pok Lundquist J, Trinkler F, Lutolf U, Krestin GP (1996) Value of endorectal coil versus body coil MRI for diagnosis of recurrent pelvic malignancies. Abdom Imaging 21:345-352
5. Leventis AK, Shariat SF, Slawin KM (2001) Local recurrence after radical prostatectomy: Correlation of US features with prostatic fossa biopsy findings. Radiology 219:432-439
6. Roudier MP, Vesselle H, True LD, et al. (2003) Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: The effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 20:171-180
7. Partin AW, Pearson JD, Landis PK, et al. (1994) Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43:649-659
8. Okotie OT, Aronson WJ, Wieder JA, Liao Y, et al. (2004) Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 171:2260-2264
9. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003) 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44:32-38
10. Picchio M, Messa C, Landoni C, et al. (2003) Value of [11C]choline-positron emission tomography for re-staging prostate cancer: A comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 169:1337-1340
11. DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE (2002) Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 43:92-96
12. DeGrado TR, Coleman RE, Wang S, et al. (2001) Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer. Cancer Res 61:110-117
13. DeGrado TR, Baldwin SW, Wang S, et al. (2001) Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 42:1805-1814
14. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR (2002) Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 168:273-280
15. Hara T, Kosaka N, Kishi H (2002) Development of (18)F-fluoroethylcholine for cancer imaging with PET: Synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 43:187-199
16. 11C]Choline [abstract]. Eur J Nucl Med 30(suppl):342P
17. Delbeke D, Martin WH (2004) PET and PET-CT for evaluation of colorectal carcinoma. Semin Nucl Med 34:209-223
18. Maldonado A, Sancho F, Cerdan J, et al. (2000) FDG-PET in the detection of recurrence in colorectal cancer based on rising CEA level. Experience in 72 patients. Clin Positron Imaging 3:170
19. Helal BO, Merlet P, Toubert ME, et al. (2001) Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 42:1464-1469
20. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M (1999) Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 36:31-35
21. Macara IG (1989) Elevated phosphocholine concentration in ras-transformed NIH 3T3 cells arises from increased choline kinase activity, not from phosphatidylcholine breakdown. Mol Cell Biol 9:325-328
22. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003) Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 44:331-335
23. Kwee SA, Coel MN, Lim J, Ko JP (2005) Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol 173:252-255
24. Liu CS, Shen YY, Lin CC, Yen RF, Kao CH (2002) Clinical impact of [(18)F]FDG-PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels: A preliminary report. Jpn J Clin Oncol 32:244-247
25. Gomez P, Manoharan M, Kim SS, Soloway MS (2004) Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: When is it indicated? BJU Int 94:299-302
26. Menzel C, Dobert N, Hamscho N, et al. (2004) The influence of CA 125 and CEA levels on the results of (18)F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer. Strahlenther Onkol 180:497-501
27. Chang TC, Law KS, Hong JH, et al. (2004) Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: A phase II study. Cancer 101:164-171
28. Coleman R, DeGrado T, Wang S, et al. (2000) Preliminary evaluation of F-18 Fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging 3:147
29. Heinisch M, Meier S, Salomon U, Panholzer PJ, Stoiber P, Langsteger W (2004) Initial experience in F18-fluorocholine PET/CT in prostate cancer - implications for the determination of a PET/CT acquisition protocol. Q J Nucl Med Mol Imaging 48(suppl):7P